Digital Therapeutics

About Us

Welcome to the 7th Global Summit on Digital Therapeutics (Digital Therapeutics-2026), taking place on April 20–21, 2026, in Barcelona, Spain. Under the visionary theme, "Future-Proofing Healthcare Through Digital Interventions," this international event will gather top minds from across healthcare, technology, pharma, and academia to explore cutting-edge advancements transforming the therapeutic landscape.

Digital Therapeutics-2026 aims to highlight the latest innovations in AI-driven treatment solutions, personalized digital care, remote patient monitoring, behavioral interventions, real-world data applications, and regulatory frameworks shaping the future of digital health. Attendees will engage in powerful discussions, evidence-based presentations, and interactive networking sessions that foster collaboration and inspire forward-thinking strategies in modern healthcare delivery.

Target Audience:

This summit is designed for digital health innovators, clinicians, healthcare professionals, pharma and biotech leaders, data scientists, researchers, regulatory experts, investors, and policy makers who are driving the evolution of software-based therapeutic solutions.

Abstract Submission Deadlines:

First Round: September 30, 2025
Second Round: January 15, 2026
Third Round: April 01, 2026

Join us in Barcelona to shape the digital health revolution and be part of a global movement redefining how healthcare is delivered and experienced.

CPD/CME/CEU points

All registered participants of the 7th Global Summit on Digital Therapeutics, taking place on April 20–21, 2026, in Barcelona, Spain, will be eligible to receive 15–20 Continuing Education Credits (CME/CEU/CPD) for full participation over both days.

These credits are awarded as part of an international commitment to lifelong learning and continuing professional development in digital healthcare and therapeutics.

CME (Continuing Medical Education) credits are particularly applicable to physicians, digital health specialists, and healthcare professionals who need accredited education to maintain their medical licensure and certification.

CEU (Continuing Education Unit) credits support the educational growth of nurses, digital health coordinators, allied health professionals, and those working in digital therapeutic deployment or support roles.

CPD (Continuing Professional Development) credits are recognized across multiple domains, enabling professionals in health tech, academia, policy, and regulatory fields to enhance their expertise and stay current with evolving technologies.

All participants will receive an official certificate detailing the number of credits earned, which may be submitted to licensing boards or accrediting bodies for formal recognition.

By attending Digital Therapeutics-2026, you will not only explore transformative advancements in digital care—but also enrich your professional profile and affirm your commitment to the future of healthcare.

Join us in Barcelona and earn as you learn—connect, innovate, and lead in the era of digital therapeutics!

Sessions

AI-Powered Personalization in Digital Therapeutics

The integration of artificial intelligence into digital therapeutics enables unprecedented levels of personalization in healthcare delivery. Leveraging patient-specific data such as biometric feedback, behavioral trends, and medical history, AI-driven platforms can adapt treatments in real-time to match an individual’s evolving needs. This approach increases engagement, improves therapeutic outcomes, and supports clinicians in making informed decisions. Predictive analytics, natural language processing, and neural networks play a vital role in customizing interventions for conditions ranging from mental health to metabolic disorders. As these technologies advance, ethical considerations, algorithm transparency, and regulatory oversight are increasingly essential. The scalability of AI-powered DTx also makes it a promising tool in managing large populations with chronic diseases. This session explores the architecture, clinical application, and regulatory pathways necessary for successful AI adoption in digital therapeutics. Attendees will gain a comprehensive understanding of how machine learning models can be trained, validated, and deployed in compliance with healthcare standards, while also addressing patient privacy and bias mitigation strategies.

Integrating DTx into Clinical Practice

Integrating digital therapeutics into routine clinical workflows requires a multidisciplinary approach that ensures both technological readiness and clinical efficacy. As DTx evolves into a recognized modality of care, aligning these tools with existing treatment guidelines and EHR systems becomes a key focus. Clinical integration involves adapting care delivery models to accommodate software-based therapies, fostering collaboration between digital developers, physicians, and healthcare systems. This effort includes training providers, ensuring reimbursement pathways, and validating efficacy through robust clinical trials. Successful integration also depends on user-friendly interfaces, real-time data sharing, and cross-platform compatibility to promote continuity of care. Challenges such as physician skepticism, lack of standardized protocols, and interoperability hurdles are being actively addressed across the industry. This topic will delve into strategic implementation plans, case studies of real-world integration, and future projections for DTx in chronic disease management and mental health. By streamlining adoption, healthcare systems can unlock the full potential of DTx to enhance patient outcomes, reduce costs, and close treatment gaps.

Behavioral Health Solutions via Mobile Platforms

Mobile platforms are becoming vital tools in delivering behavioral health interventions, offering scalable, accessible, and patient-centered support for conditions such as anxiety, depression, and PTSD. Through evidence-based modules, mood tracking, guided therapy sessions, and real-time feedback, mobile DTx platforms empower users to take an active role in their mental health journey. These tools often utilize cognitive behavioral therapy (CBT), mindfulness practices, and personalized coaching to deliver clinically validated care remotely. The flexibility of mobile access ensures continuity of care, particularly in underserved or remote communities. Moreover, integration with wearable devices enables real-time monitoring of physiological and behavioral indicators. This continuous feedback loop allows for dynamic intervention adjustments tailored to the user’s progress and engagement. Regulatory scrutiny, user data privacy, and efficacy validation remain top priorities. This discussion will explore design principles, user engagement strategies, clinical trial outcomes, and case applications that demonstrate how mobile digital therapeutics are transforming behavioral healthcare delivery at scale.

Real-World Evidence for DTx Validation

Real-world evidence (RWE) plays a pivotal role in establishing the safety, effectiveness, and utility of digital therapeutics beyond controlled clinical settings. Unlike traditional randomized controlled trials, RWE leverages data collected during routine care such as electronic health records, claims databases, patient registries, and wearable devices to evaluate therapeutic impact in diverse populations. This evidence is essential for regulatory decision-making, payer acceptance, and broader market access. For DTx developers and clinicians alike, understanding how to design studies that generate meaningful RWE is crucial to demonstrating long-term value. Key challenges include ensuring data quality, managing confounding variables, and maintaining patient privacy. Successful RWE initiatives have led to refined clinical guidelines, improved risk stratification, and enhanced patient engagement models. This topic will highlight methodologies for real-world data collection, analytics platforms that support scalable RWE generation, and case studies where RWE has driven reimbursement and regulatory approvals for digital therapeutics. Attendees will gain insight into how to use RWE strategically in evidence-based DTx innovation.

Gamification Techniques in Patient Engagement

Gamification has emerged as a powerful tool in digital therapeutics, leveraging game mechanics to enhance patient motivation, adherence, and overall engagement. By incorporating elements such as goal-setting, rewards, progress tracking, and challenges, gamified DTx platforms foster a more interactive and enjoyable user experience. These techniques are particularly effective in managing chronic diseases, promoting mental wellness, and encouraging lifestyle modifications. Game dynamics can be tailored to different age groups and therapeutic areas, with data analytics enabling real-time personalization. Clinical studies have shown that gamification can significantly improve retention and therapeutic outcomes when compared to traditional interventions. However, successful implementation requires thoughtful design to avoid trivialization of health conditions and to ensure accessibility. This session explores the psychology behind gamification, the principles of effective game-based design in therapeutic contexts, and examples of validated gamified DTx applications. Attendees will learn how to balance clinical goals with user-centric design to deliver high-impact digital interventions that resonate with patients.

Prescription DTx for Chronic Disease Management

Prescription digital therapeutics (PDTs) are redefining how chronic diseases are managed, offering FDA-approved, evidence-based interventions delivered via software. These therapeutics are designed to complement or replace traditional treatments by providing personalized care modules that address behavioral, cognitive, and physiological aspects of chronic illness. From diabetes and hypertension to substance use disorders and insomnia, PDTs offer patients daily support and clinicians actionable data. The clinical rigor behind PDTs ensures that they meet regulatory standards similar to pharmaceuticals, allowing for integration into prescribing workflows and reimbursement systems. By using secure digital platforms, PDTs enable real-time monitoring, adaptive therapy pathways, and greater treatment adherence. This model enhances patient autonomy while providing physicians with decision-support tools and long-term outcome tracking. As healthcare systems strive for more scalable and efficient chronic care solutions, PDTs represent a paradigm shift. The session explores development pipelines, regulatory pathways, payer models, and clinical evidence that make PDTs a pivotal innovation in modern healthcare.

Wearables and Remote Monitoring in DTx

The integration of wearable technology in digital therapeutics has unlocked new capabilities for real-time patient monitoring, personalized feedback, and proactive healthcare intervention. Devices such as smartwatches, biosensors, and fitness trackers collect continuous biometric and behavioral data, enabling clinicians and DTx platforms to make data-driven decisions. These tools support early detection of symptom changes, medication adherence, and lifestyle management for conditions like cardiovascular disease, diabetes, and sleep disorders. Remote monitoring enhances patient safety and engagement, especially in chronic and post-acute care settings, by bridging the gap between clinic visits. In addition to enabling telehealth services, wearables contribute to building real-world evidence that validates the long-term impact of DTx interventions. Privacy, interoperability, and user experience remain vital considerations in the deployment of wearable-integrated DTx. This session provides a comprehensive look at the evolution of wearable technologies, integration into therapeutic platforms, and regulatory and clinical frameworks shaping their use in patient-centered digital care.

Regulatory Trends in Global DTx Approval

Navigating the regulatory landscape for digital therapeutics is essential to ensuring global adoption, safety, and reimbursement. Regulatory bodies such as the FDA, EMA, and others are actively shaping new pathways to evaluate software-based medical interventions. As DTx products differ from traditional pharmaceuticals and medical devices, establishing standards for efficacy, cybersecurity, usability, and clinical validation is crucial. Globally, regulatory frameworks are evolving to address software as a medical device (SaMD), with increasing clarity on documentation, real-world evidence, and risk stratification. Harmonization across countries remains a challenge, but recent developments signal progress toward global conformity. This session explores the nuances of obtaining regulatory approval for DTx, with case examples from the U.S., Europe, and Asia-Pacific markets. It will address the role of clinical trials, regulatory sandboxes, AI regulation, and post-market surveillance in shaping policy. Attendees will gain practical insights into navigating international regulatory processes to bring compliant, scalable, and safe DTx solutions to market.

DTx and Cognitive Behavioral Therapy Integration

Digital therapeutics rooted in cognitive behavioral therapy (CBT) are becoming mainstream in addressing mental health disorders such as depression, anxiety, PTSD, and insomnia. By digitizing CBT modules, patients gain access to structured, evidence-based interventions via smartphones, tablets, or web platforms. These programs often include mood tracking, thought journals, guided exercises, and self-assessment tools that empower patients to manage their symptoms between clinical appointments. Clinician dashboards allow for tailored interventions and better understanding of patient progress. The scalability and flexibility of digital CBT make it a valuable solution for underserved populations or those hesitant to seek in-person care. Research has shown that digitally delivered CBT can be as effective as traditional therapy when implemented correctly. The success of this model depends on engagement, UX design, cultural sensitivity, and data privacy. This session focuses on the design, efficacy, and clinical applications of CBT-based DTx, offering guidance for practitioners and developers working to expand mental health care access through digital innovation.

Data Security and Privacy in Digital Health

As digital therapeutics collect and process vast amounts of sensitive health data, ensuring robust security and privacy protocols is paramount. Patients and regulators demand transparency and accountability in how personal health information is handled, stored, and shared. Compliance with frameworks like GDPR, HIPAA, and regional cybersecurity laws is non-negotiable for DTx developers and providers. Key concerns include data encryption, secure APIs, breach response plans, and consent management. As AI and real-time monitoring become embedded in DTx, these risks grow more complex, making cybersecurity an essential component of product development. Moreover, ethical considerations surrounding data ownership, informed consent, and algorithmic bias are critical to user trust. This session offers a deep dive into best practices for securing digital health data, covering threat mitigation strategies, compliance frameworks, and the role of third-party audits. Attendees will gain tools to design privacy-first DTx platforms that ensure safety while enabling innovation in patient-centered care delivery.

Combining Pharmacotherapy with Digital Tools

The integration of digital tools alongside pharmacotherapy is redefining modern treatment protocols. By blending traditional drug therapies with digital therapeutics (DTx), healthcare providers can improve patient engagement, monitor medication adherence, and tailor treatment plans based on real-time feedback. Digital platforms offer features such as personalized reminders, symptom tracking, and side effect reporting, enabling clinicians to make timely interventions. This synergy ensures that pharmacological efficacy is maximized while supporting behavioral changes and improving overall health outcomes. Particularly in chronic disease management, combining pharmacotherapy with DTx enables a more holistic and individualized approach to care. It reduces hospital readmissions, improves compliance, and fosters a stronger therapeutic alliance between patient and provider. As digital health solutions continue to advance, the pharmaceutical industry is increasingly investing in companion digital tools to augment the value of medications. Regulatory frameworks are also evolving to support combined therapy approvals, ensuring safety and efficacy. This blended model represents a significant shift toward precision medicine, enhancing both clinical and economic outcomes across healthcare systems.

Virtual Reality Applications in Therapeutic Care

Virtual reality (VR) is emerging as a transformative modality in therapeutic care by offering immersive, controlled environments for mental and physical health interventions. Through realistic simulations and gamified interactions, VR enables effective exposure therapy for anxiety disorders, phobias, PTSD, and social anxiety, creating safe spaces for patients to confront their triggers. In physical rehabilitation, VR systems promote motor skill recovery, pain distraction, and improved mobility through interactive exercises, which are proven to enhance patient motivation and adherence. The ability to customize VR environments allows for highly personalized treatments and continuous progress tracking. Additionally, VR is being explored for managing chronic pain, promoting mindfulness, and supporting cognitive behavioral therapy. Clinically validated VR platforms are increasingly being integrated into mainstream healthcare, particularly in behavioral health, pediatrics, and rehabilitation centers. As the cost of VR hardware continues to decline, access to immersive therapeutic care is becoming more scalable and feasible. The future of VR in healthcare lies in further clinical validation, regulatory acceptance, and broader adoption across disciplines to offer accessible and engaging digital care.

Blockchain for DTx Data Integrity

Blockchain technology offers a secure, decentralized framework for ensuring data integrity within digital therapeutics. In an era where healthcare data breaches are a critical concern, blockchain’s immutable ledger system guarantees that patient records, treatment protocols, and usage logs remain tamper-proof and transparent. This trust-enabling feature is particularly valuable for DTx platforms that collect, store, and share sensitive health information across multiple stakeholders. By enabling traceable consent management, blockchain also strengthens patient autonomy and compliance with privacy regulations such as GDPR and HIPAA. It facilitates the secure exchange of clinical trial data, supports interoperability between systems, and enables auditability for regulatory reviews. For developers, blockchain offers a streamlined way to validate user access, enhance authentication, and build confidence in clinical claims. For patients, it reassures them that their health data is used ethically and securely. As DTx adoption grows, incorporating blockchain into digital platforms will become vital for sustaining data security, protecting user trust, and promoting regulatory alignment in an increasingly digital health ecosystem.

Patient-Centered Design in Therapeutic Apps

A cornerstone of successful digital therapeutics is patient-centered design—an approach that prioritizes user needs, preferences, and behaviors in the development of therapeutic applications. This design philosophy ensures that DTx tools are intuitive, accessible, and tailored to diverse patient populations. From interface usability to personalized content delivery, patient involvement in the design process leads to higher engagement, better adherence, and improved clinical outcomes. Developers use iterative feedback, user testing, and co-creation strategies to ensure that apps are not only clinically effective but also resonate with patients emotionally and culturally. Accessibility features, such as voice commands, language localization, and simple navigation, ensure that digital tools are usable by individuals across age groups and health literacy levels. Additionally, incorporating motivational strategies like gamification, behavioral nudges, and real-time feedback keeps users engaged over time. Patient-centered design ultimately bridges the gap between technological innovation and real-world usability, making DTx solutions more impactful, inclusive, and sustainable. It plays a pivotal role in scaling digital health interventions that truly meet the needs of the people they aim to serve.

Reimbursement Models for Digital Interventions

Reimbursement remains a key challenge and catalyst for the adoption of digital therapeutics (DTx) globally. Developing clear and sustainable reimbursement models is essential for integrating DTx into mainstream healthcare systems. As clinical validation for digital interventions grows, payers are beginning to recognize their value in improving outcomes and reducing long-term costs, particularly in chronic disease management. Countries like Germany and the U.S. have introduced digital health frameworks allowing specific DTx products to be reimbursed, setting important precedents for others to follow. These models consider real-world evidence, usage adherence, and outcome-based payment structures. Innovative approaches such as value-based reimbursement, subscription models, and hybrid funding mechanisms are being tested across public and private systems. Collaboration between developers, payers, regulators, and providers is critical in shaping policies that support innovation without compromising safety or efficacy. The future of reimbursement for DTx will rely on robust evidence generation, interoperability with electronic health records, and clear demonstration of cost-effectiveness. With the right models in place, DTx can be scaled widely, ensuring accessibility and affordability for patients globally.

Pediatric Applications of Digital Therapeutics

Digital therapeutics are increasingly tailored for pediatric populations, addressing unique challenges in engagement, developmental needs, and parental involvement. In areas such as ADHD, autism spectrum disorders, anxiety, and obesity, DTx provides interactive, age-appropriate interventions that are both clinically effective and engaging. These tools leverage gamified elements, animations, and sensory-friendly interfaces to capture attention and deliver consistent behavioral therapies. Parental dashboards and clinician portals allow for monitoring progress, ensuring a comprehensive care approach. In addition, school-based DTx implementations are being explored to support children in real-world environments. Regulatory bodies are also beginning to approve DTx solutions specifically designed for children, highlighting their growing acceptance. Ensuring safety, data privacy, and clinical efficacy remains a top priority, especially in this vulnerable group. Ethical design, involving child psychologists and pediatricians in development stages, enhances outcomes and user trust. By providing early, accessible, and personalized support, pediatric DTx opens new doors for addressing childhood health challenges in ways that are scalable, cost-effective, and empowering for families.

Machine Learning in Outcome Prediction

Machine learning (ML) is revolutionizing how digital therapeutics predict, monitor, and optimize patient outcomes. By analyzing vast datasets—from patient-reported outcomes to biometric data—ML algorithms can identify patterns and trends that human analysis may miss. These insights enable early detection of treatment non-responsiveness, risk of relapse, or adverse events, allowing for timely and precise interventions. ML-driven models also support adaptive learning, continuously improving predictions as more data is collected, ensuring the therapeutic pathway remains dynamic and personalized. In chronic diseases, behavioral health, and rehabilitation, outcome prediction tools are proving vital for long-term patient management and resource allocation. Furthermore, ML is being used in trial design to optimize inclusion criteria, forecast adherence, and simulate therapeutic scenarios. Developers must, however, prioritize transparency, algorithm validation, and bias mitigation to maintain clinical integrity. As regulatory frameworks evolve, ML-powered DTx solutions will play a vital role in delivering proactive, patient-specific care that enhances efficiency and improves health outcomes across populations.

Voice and Chatbot Interfaces for Therapy Delivery

The integration of voice assistants and chatbot interfaces into digital therapeutics is transforming the way patients interact with therapy tools. These interfaces offer real-time, conversational support for mental health, medication adherence, chronic disease management, and lifestyle coaching. Designed with natural language processing (NLP), these tools deliver therapeutic interventions through empathetic dialogue, reminders, and behavioral prompts. For patients who struggle with traditional apps—due to vision issues, low digital literacy, or accessibility needs—voice interfaces offer a user-friendly alternative. Chatbots can simulate cognitive behavioral therapy sessions, monitor mood changes, or guide breathing exercises, ensuring continuous therapeutic engagement. The 24/7 availability of these tools also reduces the burden on healthcare professionals, while collecting meaningful data for clinical oversight. Developers must focus on privacy, accuracy, and cultural sensitivity to ensure these AI-driven interactions are ethical and effective. As technology advances, voice and chatbot interfaces will continue to humanize digital healthcare by delivering timely, accessible, and scalable therapeutic conversations.

Interoperability Between DTx and EHR Systems

Seamless interoperability between digital therapeutics (DTx) platforms and electronic health record (EHR) systems is critical for the integration of digital health into clinical workflows. By enabling real-time data exchange, interoperability allows clinicians to access patient progress, adjust treatment plans, and ensure cohesive care delivery. DTx-generated data—including adherence metrics, symptom tracking, and behavioral trends—becomes actionable only when integrated with broader clinical records. Standards such as HL7 FHIR and APIs are driving efforts to bridge the gap between standalone DTx tools and hospital systems. Enhanced interoperability not only improves provider decision-making but also supports reimbursement and regulatory reporting. Developers must ensure compliance with privacy standards like HIPAA and GDPR while maintaining data integrity and security during transmission. Interoperable systems also empower patients, as their treatment insights become part of a holistic health journey. Moving forward, industry collaboration is essential to build platforms that support scalable, plug-and-play integration with diverse EHR ecosystems, accelerating digital adoption in clinical care.

DTx Innovations in Preventive Healthcare

Digital therapeutics are increasingly being leveraged in the domain of preventive healthcare, addressing lifestyle-related diseases and promoting early interventions. By targeting behaviors such as diet, sleep, exercise, and stress management, DTx solutions empower users to make sustainable health choices before the onset of disease. These platforms use behavioral science, real-time feedback, and AI personalization to deliver tailored recommendations that align with an individual’s health goals. Preventive DTx applications have shown promise in areas like prediabetes management, cardiovascular risk reduction, and mental wellness promotion. Wearables and remote monitoring tools enhance the experience by capturing biometric data that informs intervention strategies. Preventive models supported by digital therapeutics reduce healthcare costs, lower hospital admissions, and improve population health outcomes. As public health systems shift from treatment-focused to wellness-oriented models, DTx plays a pivotal role in this transition. The scalability, affordability, and adaptability of digital interventions make them ideal tools for health promotion across communities and age groups.

Market Analysis

The global digital therapeutics (DTx) market has witnessed substantial growth over the past few years, driven by a surge in demand for personalized, technology-enabled healthcare solutions that address chronic conditions, mental health disorders, and lifestyle-related diseases. As healthcare systems around the world grapple with rising costs and limited resources, digital therapeutics have emerged as a viable, scalable, and cost-effective alternative or supplement to traditional medical interventions. These software-driven therapies offer clinically validated interventions, often grounded in behavioral science, and are capable of preventing, managing, or treating a broad range of conditions, from diabetes and hypertension to depression and ADHD. The digital therapeutics market was valued at approximately USD 6.1 billion in 2023 and is projected to surpass USD 25 billion by 2030, growing at a CAGR of over 20%. This rapid expansion is being fueled by increasing smartphone penetration, the proliferation of wearable health devices, and growing public awareness of preventive health. Furthermore, regulatory bodies such as the U.S. FDA, the European Medicines Agency (EMA), and other regional authorities have begun to establish clear approval pathways and digital health frameworks, creating fertile ground for innovation, investment, and global market expansion.

The European digital therapeutics sector in particular is advancing rapidly, supported by progressive healthcare policies, reimbursement schemes, and digital health adoption initiatives. Germany’s Digital Health Act (DVG), for example, has paved the way for approved DTx apps to be prescribed by physicians and reimbursed through statutory health insurance. Other countries including France, the UK, and the Nordics are following suit with pilot projects and national frameworks aimed at integrating DTx into primary care systems. Barcelona, as a burgeoning digital health hub with strong biotech and medtech ecosystems, serves as an ideal location for convening international leaders in the field at Digital Therapeutics-2026. Investment in DTx continues to rise steadily, with both venture capital and strategic partnerships playing key roles in product development and market penetration. Major pharmaceutical companies are collaborating with digital health startups to co-develop digital companion products and combination therapies, while insurers and health systems are increasingly open to piloting DTx for remote monitoring, adherence, and behavior modification. Artificial intelligence, real-world evidence, machine learning, and blockchain are being integrated into digital therapeutic models to enhance personalization, security, and treatment outcomes. These advancements also allow for adaptive interventions that evolve with patient needs and real-time feedback loops. Despite its promising trajectory, the DTx market faces challenges related to data security, user engagement, clinical validation, and reimbursement scalability. Addressing these barriers will require greater cross-sector collaboration among developers, regulators, healthcare providers, and payers. Stakeholders must also focus on standardizing metrics for clinical efficacy, improving interoperability with electronic health records (EHRs), and refining patient-centered design principles to increase usability and adoption across diverse demographics. Special attention is also required for pediatric, geriatric, and underserved populations, who stand to benefit greatly from targeted DTx interventions.

Looking ahead, the integration of digital therapeutics into mainstream healthcare is not only inevitable it is essential for building resilient, value-based, and patient-centric health systems. The 7th Global Summit on Digital Therapeutics will provide a strategic platform for discussing these opportunities and addressing current challenges. By bringing together global experts, innovators, clinicians, policymakers, and investors, the event aims to accelerate the adoption of evidence-based digital interventions and shape the future of therapeutic care. Participants will explore cutting-edge applications, regulatory frameworks, real-world use cases, and partnership models that define the evolving DTx landscape. As healthcare continues its transformation in the digital era, digital therapeutics stand at the forefront—delivering measurable impact, enhancing clinical outcomes, and redefining how we prevent, treat, and manage disease. Digital Therapeutics-2026 in Barcelona marks a pivotal milestone in this journey, inviting all stakeholders to join the movement toward a smarter, more connected, and more compassionate healthcare ecosystem.

Past Conference Report

Digital Therapeutics-2023

Conferences are an essential forum for academic researchers and business leaders. It involves multiple presentations, interactive breakout sessions, hands-on product demonstrations, and unparalleled networking opportunities. We've invited some of the world's most sought-after speakers, experts, brand ambassadors and industry leaders to share their thoughts and insights with our conference guests.

On behalf of the 6th Global Summit on Digital Therapeutics, we are delighted to welcome you to join the Conference which is going to be held in beautiful city Los Angeles, USA during Oct 23-24, 2023 with the theme of “Defining the New Age of Digital Therapeutics”. This is an exceptional gathering for the worldwide prominent scholastics in the field of Obesity and Nutritional Health where Directors, Scientists, Professors, Research scholars, Postdocs, Academic Staff are about to share their research work and acquiesce new emerging technological trends in the conference areas. This GSDT-2023 makes a perfect platform for global networking as it brings together the renowned speakers, professors, scientists, educationalists, researchers and students across the globe to a most exciting, exceptional, memorable scientific leading event to report and witness the latest scientific achievements in obesity in broad range of scientific fields. This is a great opportunity for delegates from universities and institutes to connect with the world-class scientists and speakers during our "Digital Therapeutics 2023" to discuss new advances in the field of therapeutics and building to improve wellness and treatment and additionally supplement.